Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Stuart Baker x
  • Refine by access: Open Access content only x
Clear All Modify Search
Stuart Baker FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, UK

Search for other papers by Stuart Baker in
Google Scholar
PubMed
Close
,
Ricardo Núñez Miguel FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, UK

Search for other papers by Ricardo Núñez Miguel in
Google Scholar
PubMed
Close
,
Daniel Thomas FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, UK

Search for other papers by Daniel Thomas in
Google Scholar
PubMed
Close
,
Michael Powell FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, UK

Search for other papers by Michael Powell in
Google Scholar
PubMed
Close
,
Jadwiga Furmaniak FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, UK

Search for other papers by Jadwiga Furmaniak in
Google Scholar
PubMed
Close
, and
Bernard Rees Smith FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, UK

Search for other papers by Bernard Rees Smith in
Google Scholar
PubMed
Close

Determination of the structure of the extracellular domain of human thyroid peroxidase (hTPO) by cryo-electron microscopy (cryo-EM) is described. TPO, purified to homogeneity was complexed with the hTPO monoclonal autoantibody 2G4 Fab and also with a mouse monoclonal TPO antibody 4F5 Fab (which competes with autoantibody binding to TPO). Both complexes were analysed by cryo-EM. The two structures (global resolution 3.92 and 3.4 Å for the 2G4 complex and 4F5 complex, respectively) show TPO as a monomer with four domains; the N-terminal domain, the peroxidase domain (POD), the complement control protein (CCP)-like domain and the epidermal growth factor-like domain which are all visible in the structures. The relative positions of the domains are fixed with a disulphide bond between cysteine residues Cys146 in the POD and Cys756 in the CCP domain preventing significant flexibility of the molecule. The entrance to the enzyme active site, the haem group and the calcium binding site are clearly visible on the opposite side of the TPO molecule from the 2G4 and 4F5 binding sites. Extensive interactions are seen between TPO and the two antibodies which both bind to distinct epitopes on the POD domain, including some residues in the immunodominant region B mainly via different residues. However, the epitopes of the two antibodies contain three shared TPO residues. This is the first high-resolution structure of TPO to be reported and it should help guide the development of new inhibitors of TPO enzyme activity for therapeutic applications.

Open access